Key facts
- Iterion Therapeutics presented clinical validation data for tegavivint.
- Tegavivint targets Wnt-driven advanced hepatocellular carcinoma (HCC).
- The therapy demonstrated monotherapy clinical responses.
- Tegavivint showed on-target Wnt/b-catenin pathway inhibition in patients with Wnt-pathway mutated advanced HCC.
Hepatocellular carcinoma (HCC) is a common form of liver cancer. The Wnt/b-catenin pathway plays a significant role in the development and progression of many cancers, including HCC. Therapies that can specifically inhibit this pathway in patients with relevant mutations offer a targeted approach to treatment. Iterion Therapeutics' tegavivint aims to provide such a targeted therapy, and its clinical validation suggests potential for patients with limited treatment options.